FMT Cohort
CHUM
CAN
45
Prospective, Interventional
NSCLC, Cutaneous Melanoma, Uveal
MIMic
CHUM
CAN
20
Prospective, Interventional
Melanoma
NSCLC Biobank
CHUM
CAN
250
Prospective
NSCLC
NSCLC Biobank - Neoadjuvant
CHUM
CAN
53
Prospective
Limited NSCLC stage II-III
NSCLC Biobank
CHUM
CAN
500
Retrospective
Advanced NSCLC stage III-IV
Diet Cohort
CHUM
CAN
30
Prospective, Interventional
Limited NSCLC stage II-III and Advanced NSCLC stage III-IV
Camu-Camu Cohort
CHUM
CAN
45
Prospective, Interventional
Advanced NSCLC, Melanoma 1st - 2nd line treatment
Melanoma
CHUM
CAN
410
Prospective
Cutaneous, Ocular and Mucosal Melanoma
POINTING/COLIPI
UMCG
NL
385
Observational
NSCLC stage III-IV
OncoLifeS
UMCG
NL
465
Prospective, Observational
HCC, Head & Neck, Melanoma, Renal Cell, Urothelial and other
LifeLines
UMCG
NL
167.000
Prospective, Observational
General Population
Lifelines DAG3 (Dutch Microbiome Project)
UMCG
NL
8.208
Prospective, Observational
General Population
PALGA - Lifelines
UMCG
NL
8.208
Prospective, Observational
General Population,
CRC/adenoma, Head & Neck and other
PharmLines
UMCG
NL
110.000
Prospective, Observational
General Population
PULSE
IGR
FR
Observational
NSCLC
ONCOBIOTICS
IGR
FR, CAN
Prospective, Observational
Pan-cancer Cohort
NSCLC
IGR
FR, CAN
481 (TOPOSCORE excluded IML1)
NSCLC
RCC
IGR
FR
205
RCC
Immunolife1
IGR
FR
162 (ATB paper)
NSCLC, RCC, UC
Others
IGR
FR
Others
ClinicObiome STING (IGR, FR)
IGR
FR
Prospective, Observational
Pan-cancer Cohort
NSCLC
IGR
NSCLC
RCC
IGR
RCC
Immunolife1
IGR
NSCLC, RCC, UC
Others
IGR
Others
ONCOBIOME
IGR
FR
Retrospective, Prospective
IOPREDI
AZ
FR
UC
MIND-DC
IGR
NL
88
Melanoma
CARMENET
IGR
BR
62
Neuroendocrine Tumors
BISQUIT
IGR
BR
34
Anal cancer
Atezotribe
IGR
IT
185
CRC
OVBIOMARK
IGR
FR
80
Gyneco
CANTO
IGR
FR
240
BC
SABR
Prostate
Prosate
CRC
IBOOST
Pan-MSI-ACSE
IGR
FR
Observational
MSI (non colon, non gyneco)
ICARUS (IGR, FR)
IGR
FR
Observational
BC
TOPOSCORE GMT
(NSCLC and other)
IGR
FR
400
Observational
NSCLC
IMMUNOLIFE 2 NSCLC
IGR
FR
162
Interventional
NSCLC
sTOOLBOOST
IGR
FR, BR, IT
300
Interventional
NSCLC, RCC
STARLIGHT
IGR
IT
46 (A) / 276 (B)*
Interventional
NSCLC
MDSC study
IGR
IT
60*
Observational
NSCLC
POP-DURVA
IGR
FR
240 (Ongoing)
Observational
BC
LEAH
IGR
FR
Planned >1000
Observational
Others
PREVALUNG EU
IGR
FR, IT
Planned >1000
Observational
Others
Lifestyle cohort (Science 2021)
MDA
US
438
Observational
Melanoma